At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action AMPA receptor antagonists; GABA A receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 25 Jun 2001 No-Development-Reported for Epilepsy in USA (PO)
- 14 Jul 1998 Preclinical development for Epilepsy in USA (PO)